Clinical Trial Search

Primary: Acceptability of the Intervention Measured by the Study Visit Satisfaction Form FACT Was Helpful — 26; 3 Participants

Primary: Shannon Diversity Index Measuring Change in Microbiome Diversity — 0.18; 0.14 Shannon index — p=0.71

Primary: Neonatal Mortality — 46; 37 Participants — p=0.314

Primary: Mean Nutrition Environment Score — 1.88; 1.98; 2.06; 2.08 score on a scale — p=0.101

Primary: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Measured Non Zero Concentration (AUC0-t) of CVN424 Suspension Fasted and Tablet Fasted…

Primary: Progression Free Survival — 4.23; 3.93 months — p=0.130

Primary: Percentage of Participants Who Achieve a ≥75% Improvement in the Eczema Area and Severity Index Score (EASI75) of the Head and Neck Region at Week 4 — 17.4; 37.0…

Primary: Proportion of Patients With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Specific Interest — 28; 27; 3; 3 Participants

Primary: Mean Change in UCLA Loneliness Scale Score (Both Cohorts) — 42.96; 45.08; 41.95; 42.47 score on a scale

Primary: Visual Analogue Pain Scale (Burning Pain) — 6.99; 3.78 units on a scale — p=<0.001

Primary: Number of Calories Purchased — 458; 477 calories

Primary: Number of Participants With ≥1 Adverse Event (AE) — 13; 4; 4; 5 Participants

Primary: Occurrence of Treatment Emergent Adverse Events (TEAEs) — 7 Participants

Primary: Evaluate the Adaptation to Progressive Lens Designs. — 4.125; 4.025; 3.875; 3.725 score on a scale

Primary: Evaluate the Pain Felt in Patients Who Have Benefited From a Hypnosis Session Before a Hand Infiltration Versus Hand Infiltration Without Hypnosis — 4.56; 1.75 units on…